$5 now possible by March............................................
The Phase 1 clinical trial of Kevetrin targeting solid tumors at Dana-Farber Cancer Center and Beth Israel Deaconess Medical Center is progressing as expected with the next cohort to begin treatment at escalated dosing levels. Studies evaluating the p21 biomarker will soon begin and the first data report is expected in mid-March.
This is the statement I have wanted to see in a PR before I could say KICK THE TIRES AND LIGHT THE FIRES BABY...........we are ON OUR WAY